
    
      The purpose of this study is to assess the reduction in treatment burden during 12 weeks of
      trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy
      only. Eligible participants will be randomized to either the study drug (trelagliptin) group
      or the comparative drug (daily DPP-4 inhibitor) group. Treatment burden will be assessed
      using Diabetes Therapy Related -QOL (DTR-QOL) questionnaire and Diabetes Treatment
      Satisfaction Questionnaire (DTSQ).
    
  